Overall, these results indicate that the novel anti-CEA RevTMs successfully redirect RevCAR T-cells to effectively kill CEA-expressing colon cancer cell lines and to promote secretion of proinflammatory cytokines. The gene discussed is CEACAM5; the disease is colonic neoplasm.